These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2612235

  • 1. Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients.
    Bucaneve G, Menichetti F, Minotti V, Pasticci MB, Tonato M, Del Favero A.
    Chemotherapy; 1989; 35 Suppl 2():10-5. PubMed ID: 2612235
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
    Liu CY, Wang FD.
    Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
    [Abstract] [Full Text] [Related]

  • 3. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R.
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [Abstract] [Full Text] [Related]

  • 4. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, Andrien F, Baudrihaye M, Bow E, Burman LA.
    Scand J Infect Dis Suppl; 1987 Apr; 52():65-78. PubMed ID: 3331044
    [Abstract] [Full Text] [Related]

  • 5. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C, Belgian Multicenter Study Group.
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [Abstract] [Full Text] [Related]

  • 6. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
    Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK, Todd D.
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252
    [Abstract] [Full Text] [Related]

  • 7. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, Viot M, Soler-Michel P, Rollin C, Grès JJ.
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [Abstract] [Full Text] [Related]

  • 8. [Monotherapy, empirical and targetted, with imipenem-cilastatin in sepsis of bacterial origin].
    Fiorentino F, De Sena R, Manzillo E, Iadanza A, Conte M, Coppola MG, Galderisi P, Postiglione A, Arciello MT, Covelli B.
    Clin Ter; 1989 May 31; 129(4):287-91. PubMed ID: 2527122
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
    Bosseray A, Nicolini F, Brion JP, Michallet M, Hollard D, Stahl JP, Micoud M.
    Pathol Biol (Paris); 1992 Oct 31; 40(8):797-804. PubMed ID: 1484739
    [Abstract] [Full Text] [Related]

  • 12. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease.
    Petrilli AS, Melaragno R, Barros KV, Silva AA, Kusano E, Ribeiro RC, Bianchi A.
    Pediatr Infect Dis J; 1993 Nov 31; 12(11):916-21. PubMed ID: 8265281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A.
    J Antimicrob Chemother; 2017 Sep 01; 72(9):2616-2626. PubMed ID: 28575389
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
    Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, Lew D.
    Infection; 2007 Jun 01; 35(3):161-6. PubMed ID: 17565457
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.